There are currently shortages of the Fiasp FlexTouch insulin pen which could affect people living with diabetes who take Fiasp insulin. Here’s what you need to know.
What’s the situation?
Fiasp is a rapid-acting insulin manufactured by Novo Nordisk. There is no current shortage of the insulin, however there is a shortage which impacts the FlexTouch insulin pen.
Fiasp FlexTouch is a disposable, pre-filled pen designed to be used with pen needles.
Shortages began in April 2024, and it is expected that Fiasp FlexTouch 100units/ml pre-filled pens will be out of stock until January 2026.
There are other ongoing insulin shortages - you can find out more here.
Why is there a shortage of Fiasp FlexTouch?
The current shortage is due to disruption in the manufacturing process of FlexTouch pens.
What is the alternative?
Novo Nordisk manufactures Fiasp in 100units/ml cartridges (Penfill), which remain available.
Due to the temporary FlexTouch shortage, your healthcare team might give you the option of continuing to use this insulin in cartridge form, but you will require a re-useable NovoPen that takes the cartridges.
Your healthcare team should provide you with a prescription for the pen device and show you how to use it. You should be advised too that you may need to more closely monitor your blood sugar levels during this time.
More information and support on Fiasp FlexTouch
Ring our helpline with any questions or concerns on 0345 123 2399
Learn more about treating diabetes with tablets and medication.
